Halozyme Announces Takeda Received Regulatory Approval for HYQVIAยฎ 10% Subcutaneous Injection Set with ENHANZEยฎ in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia PR...
Halozyme Announces argenx's VYDURA with ENHANZEยฎ was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO, Dec. 30, 2024 SAN DIEGO...
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantigโข with ENHANZEยฎ for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivoยฎ (nivolumab) Indications PR...
Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 27, 2024 SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today...
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions PR Newswire SAN DIEGO, Nov. 22, 2024 SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme...
Halozyme Confirms Proposal to Combine with Evotec for โฌ11.00 Per Share in an All-Cash Transaction PR Newswire SAN DIEGO, Nov. 14, 2024 Combination Would Create a Global Innovative Services...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | -6.38 | -99.6875 | 6.4 | 9.2 | 0.015 | 1237362 | 0.4939303 | CS |
260 | -0.405 | -95.2941176471 | 0.425 | 35 | 0.015 | 2666733 | 0.36991871 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.